Opexa Therapeutics Enters into Certain Sales Agreement with IFS Securities

On March 25, 2016, Opexa Therapeutics, Inc.

entered into that certain Sales Agreement (the "Agreement") with IFS Securities, Inc. (doing business as Brinson Patrick, a division of IFS Securities, Inc.) (the "Sales Agent"), under which the Company may sell shares of its common stock from time to time depending upon market demand, with the Sales Agent acting as an agent for sales. Pursuant to the Agreement, the Company may offer and sell the shares in transactions deemed to be an "at-the-market" offering as defined in Rule 415 of the Securities Act of 1933. The Agreement replaces that certain Sales Agreement dated September 6, 2012, as amended on March 5, 2014 (as amended, the "Original Sales Agreement"), between the Company and Meyers Associates, L.P. (doing business as Brinson Patrick, a division of Meyers Associates, L.P.) ("Meyers Associates") which was terminated. The Company will pay the Sales Agent a commission equal to 3% of the gross proceeds from the sale of shares of common stock by it as agent under the Agreement. The Agreement provides that the company will provide customary indemnification rights to the Sales Agent. The Company has no obligation to sell any shares of common stock pursuant to the Agreement and may at any time suspend sales pursuant to the Agreement. Either party may terminate the Agreement at any time without liability of any party. The shares of common stock will be sold pursuant to a new shelf registration statement on Form S-3 (Registration No. 333-208314), declared effective by the Securities and Exchange Commission on March 25, 2016. A prospectus supplement relating to the offer and sale of up to 1,000,000 shares of common stock pursuant to the Agreement will be filed with the Securities and Exchange Commission as part of the new shelf registration statement. Interested investors should read the registration statement and prospectus supplement and all documents incorporated therein by reference. This Current Report shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state. As a result of the foregoing, the continuous offering through Meyers Associates pursuant to a prospectus supplement dated March 5, 2014 is deemed terminated and no further shares will be offered or sold by the Company through Meyers Associates. The foregoing description of the Agreement does not purport to be complete and is subject to and qualified in its entirety by reference to the Agreement, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.